Zentiva

Last updated
Zentiva Group, a.s.
Industry Pharmaceuticals
Headquarters Prague, Czech Republic
Key people
Steffen Saltofte (Chief Executive Officer)
Parent Advent International
Website zentiva.com

Zentiva is a pharmaceutical company based in Prague, Czech Republic. The company is developing, manufacturing and marketing a wide range of generic and OTC products.

Contents

Zentiva employs more than 4 700 [1] people across Europe and has three manufacturing sites, in Prague, Bucharest and Ankleshwar. [2] Since 2018, Zentiva is wholly-owned by private equity firm Advent International; it was formerly, since 2008, a subsidiary of Sanofi.

History of Zentiva

The roots of the Czech pharmaceutical company date back to 1488 with At the Black Eagle's pharmacy (“U Černého Orla”) located in the Prague city center: Malá Strana. In 1857 the pharmacy was bought by Benjamin & Karel Fragner (1824-1886). [3] His expansion plans were started by his son Dr. Karel Fragner (1861-1926) and further expanded by Dr.Ing. Jiří Fragner (1900-1977). He, together with his brother, an architect Jaroslav Fragner, built and designed a new modern pharmaceutical factory in Dolní Měcholupy, which is now a part of Prague. Today Zentiva's headquarters are located on the original factory premises.

The factory “Benjamin Fragner” started to produce medicines in August 1930. Its profitability was set upon a solid bedrock of active substances, with which intensive Research and Development started. During World War II, after Czech universities were shut down following Nazi-occupation, the Fragner factory became a refuge for many notable specialists. For example, one of the first successful isolation of penicillin (BF Mykoin 510) was achieved on this site.

In 1946 [4] the company is nationalised by the Czech government and the factory and the pharmacy are split apart. The factory became part of SPOFA (United Pharmaceutical Enterprises) employing 750. It was the leading pharmaceutical site in post-war Czechoslovakia. In the early sixties, to satisfy the demand of growing need of dosage forms, the question of upgrading the site to further increase the manufactured amounts was raised. The upgrade was completed in 1979 and led to the construction of new modern production facilities.

Starting with the Velvet Revolution in 1989 the company went through a series of significant organisational and ownership changes. In 1993, the company's name was changed from Léčiva a.s. to Zentiva k.s. Later in 1998, Zentiva's management acquired a majority of shares and established a new focus on branded generic medicines. In 2003 a new corporate brand name was introduced: Zentiva CZ s.r.o.. In the same year, the leading pharmaceutical company from Slovakia [5] (Slovakofarma) was added to Zentiva portfolio. In 2004, Zentiva is listed at the Prague and London Stock Exchanges. Zentiva also expanded to Poland and Russia and other markets of central and eastern Europe. Later in 2005: Sicomed (leading generic company in Romania nowadays Zentiva SA) was acquired and added to Zentiva portfolio.

In the beginning of 2007 Zentiva increased its activity in Hungary and acquired Eczacibaşi Generic Pharmaceuticals (leading Turkish manufacturer). [6] The year 2008 marked the acquisition of Zentiva by the French holding Sanofi and decided to make it its European generics platform. Zentiva became then part of the Sanofi Generics Franchise.

In 2018, Advent International bought the European division of Sanofi's Generics business – Zentiva. Transaction of total worth 1,919 bn€. . [7] Zentiva with the support of Advent International, one of the biggest equity funds, became independent.

Following the acquisition by Advent International, Zentiva entered in a fast-paced series of acquisition to build up its position in generics and OTC markets, in and outside Europe. In April 2019, Zentiva acquired Creo Pharmaceuticals, [8] a UK-based subsidiary of the US-based Amneal Pharmaceuticals since 2013. Followed, in May, by Solacium the Romania-based pharmaceutical company expanding both its Generics and OTC footprint. [9]

In January 2022, Zentiva received the Top Employer recognition from the Top Employer Institute in the Czech Republic and Romania. [10]

Acquisitions History

Related Research Articles

Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

Ovation Pharmaceuticals is an American manufacturer and distributor of pharmaceuticals products. It was founded in 2000 by Jeffrey Aronin and is headquartered in Deerfield, Illinois. A major office is also located near Lebanon, New Jersey. Ovation is a privately held corporation based on a business model of acquiring mature but under-promoted pharmaceuticals, as well as pharmaceutical candidates which are far along the development and FDA certification processes. Since 2009, the company has been wholly owned by the Danish pharmaceutical company Lundbeck.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

<span class="mw-page-title-main">Zydus Lifesciences</span> Indian multinational pharmaceutical company

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacturing of generic drugs. The company ranked 100th in the Fortune India 500 list in 2020.

<span class="mw-page-title-main">Stada Arzneimittel</span> German pharmaceutical company

Stada Arzneimittel AG is a pharmaceutical company based in Bad Vilbel, Germany which specializes on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In 2022, revenue totaled €3.79 billion.

<span class="mw-page-title-main">Advent International</span> Global private equity firm

Advent International Corporation is an American global private equity firm focused on buyouts of companies in Western and Central Europe, North America, Latin America and Asia. The firm focuses on international buyouts, growth and strategic restructuring in five core sectors.

<span class="mw-page-title-main">Stiefel Laboratories</span> American corporation

Stiefel Laboratories Inc. is an American dermatological pharmaceutical company, with its global headquarters in Research Triangle Park, North Carolina. It makes products such as Duac and Oilatum. Stiefel was acquired by GSK plc at a price of $2.9 billion. The company was founded in 1847 by John David Stiefel, who initially created medicated soaps.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Teva API is an international pharmaceutical company headquartered in Israel. Teva API is a stand-alone business unit of Teva Pharmaceutical Industries limited, the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India. Its market presence is in more than 100+ countries.

<span class="mw-page-title-main">Flagship Food Group</span>

Insignia International, formerly Flagship Food Group, is a global, diversified food company serving some retail, grocery, food service, and food-related organizations. Flagship was rebranded in March 2024.

<span class="mw-page-title-main">Vianex S.A.</span> Greek pharmaceutical company

Vianex S.A. is a Greek pharmaceutical company, founded in 1971 by the Giannakopoulos’ family that has been involved with the pharmaceutical industry since 1924.

Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

Wilhelm Róbert Wessman is an Icelandic business executive and founder of the pharmaceutical and biotechnology companies Alvotech and Alvogen.

References

  1. ↑ "Zentiva". Zentiva Corporate Website. February 9, 2022.
  2. ↑ "Zentiva Corporate Website". August 4, 2020.
  3. ↑ www.obsah.info. "Fragnerova lékárna U Černého orla, Malostranské náměstí, Praha". www.lekarna-orel.cz. Retrieved 2020-01-07.
  4. ↑ www.obsah.info. "Fragnerova lékárna U Černého orla, Malostranské náměstí, Praha". www.lekarna-orel.cz. Retrieved 2020-01-07.
  5. ↑ "Archived copy" (PDF). Archived from the original (PDF) on April 25, 2012. Retrieved November 12, 2011.{{cite web}}: CS1 maint: archived copy as title (link)
  6. ↑ in-pharmatechnologist.com. "Zentiva snaps up Eczacibasi generics for €460m". in-pharmatechnologist.com. Retrieved 2020-01-07.
  7. ↑ "Acquisition of Sanofi's Zentiva is Completed by Advent International". PharmTech.
  8. ↑ PS, Lakshmi (2019-04-04). "Zentiva acquires Creo Pharma". Latest Pharmacy News | Business | Magazine - Pharmacy Business. Retrieved 2019-05-21.
  9. ↑ Zentiva. "Zentiva Announces Completion of Solacium Pharma Acquisition". www.prnewswire.co.uk. Retrieved 2020-01-07.
  10. ↑ Zentiva. "Zentiva awarded Top Employer accolade". www.prnewswire.com. Retrieved 2022-02-09.
  11. ↑ "Alvogen And Zentiva Complete CEE Deal". Generics Bulleting. April 20, 2020.
  12. ↑ Zentiva. "Zentiva Expands Production Capacity by Completing Acquisition of Ankleshwar Manufacturing Site". www.prnewswire.com. Retrieved 2020-06-01.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.